The Economic Burden of Patients with Diabetic Peripheral Neuropathic Pain Based on a Real-World Study in China

Rosa Wang,1 Dennis D Xuan,2 Jianwei Xuan,3 Dong Dai,1 Xin Ye,1 Xiaohan Hu3 1Global Health Economics and Outcomes Research, Daiichi Sankyo, Inc., Basking Ridge, NJ, USA; 2Department of Health Policy and Management, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA, USA; 3Health Economic Research Institute, Sun Yat Sen University, Guangzhou, People’s Republic of ChinaCorrespondence: Dong Dai, Global Health Economics and Outcomes Research, Daiichi Sankyo Inc., 211 Mt Airy Road, Basking Ridge, NJ, 07920, USA, Email [email protected]: Currently, there is no specific characterization of the economic burden of Diabetic Peripheral Neuropathic Pain (DPNP) in most Asian countries. The purpose of this study was to understand the economic burden of DPNP in China from a healthcare system perspective.Methods: The analysis was conducted using the SuValue® database, a large electronic medical record (EMR) database which covers 182 hospitals across 22 provinces in China. A 12-month baseline and 12-month follow-up period were used to compare healthcare resource utilization and costs before and after the initial diagnosis of DPNP.Results: A total of 7373 adult patients with DPNP were identified and 4220 (57.24%) patients were treated. Analgesics (n=2044, 48.44%) and anti-inflammatory drugs (n=1990, 47.16%) were the most used treatments. Among DPNP treated patients, the mean (SD) total all-cause healthcare costs during follow-up period were 8980.83 (17,721.48) CNY, with a 4446.48 CNY increase (p-value < 0.001) from 4534.35 (9791.93) CNY at baseline. The cost increase was primarily driven by an increase in hospitalization and medication costs after the DPNP diagnosis. A similar trend in the treatment pattern and total cost increase after DPNP diagnosis was also found in a sensitivity analysis when excluding over-the-counter (OTC) products from the analysis.Conclusion: DPNP is associated with significantly increased utilization of healthcare services and costs for patients in China.Keywords: diabetic peripheral neuropathic pain, economic burden, healthcare resource utilization, cost

Institutions

Publication Details

Journal
SHILAP Revista de lepidopterología
Published
2025-06-01
Primary Topic
Magnetic confinement fusion research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The Economic Burden of Patients with Diabetic Peripheral Neuropathic Pain Based on a Real-World Study in China

SHILAP Revista de lepidopterología
Magnetic confinement fusion research
article

The Economic Burden of Patients with Diabetic Peripheral Neuropathic Pain Based on a Real-World Study in China

article en

Abstract

Rosa Wang,1 Dennis D Xuan,2 Jianwei Xuan,3 Dong Dai,1 Xin Ye,1 Xiaohan Hu3 1Global Health Economics and Outcomes Research, Daiichi Sankyo, Inc., Basking Ridge, NJ, USA; 2Department of Health Policy and Management, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA, USA; 3Health Economic Research Institute, Sun Yat Sen University, Guangzhou, People’s Republic of ChinaCorrespondence: Dong Dai, Global Health Economics and Outcomes Research, Daiichi Sankyo Inc., 211 Mt Airy Road, Basking Ridge, NJ, 07920, USA, Email [email protected]: Currently, there is no specific characterization of the economic burden of Diabetic Peripheral Neuropathic Pain (DPNP) in most Asian countries. The purpose of this study was to understand the economic burden of DPNP in China from a healthcare system perspective.Methods: The analysis was conducted using the SuValue® database, a large electronic medical record (EMR) database which covers 182 hospitals across 22 provinces in China. A 12-month baseline and 12-month follow-up period were used to compare healthcare resource utilization and costs before and after the initial diagnosis of DPNP.Results: A total of 7373 adult patients with DPNP were identified and 4220 (57.24%) patients were treated. Analgesics (n=2044, 48.44%) and anti-inflammatory drugs (n=1990, 47.16%) were the most used treatments. Among DPNP treated patients, the mean (SD) total all-cause healthcare costs during follow-up period were 8980.83 (17,721.48) CNY, with a 4446.48 CNY increase (p-value < 0.001) from 4534.35 (9791.93) CNY at baseline. The cost increase was primarily driven by an increase in hospitalization and medication costs after the DPNP diagnosis. A similar trend in the treatment pattern and total cost increase after DPNP diagnosis was also found in a sensitivity analysis when excluding over-the-counter (OTC) products from the analysis.Conclusion: DPNP is associated with significantly increased utilization of healthcare services and costs for patients in China.Keywords: diabetic peripheral neuropathic pain, economic burden, healthcare resource utilization, cost

SHILAP Revista de lepidopterología
Health Economics and Outcomes Research (United Kingdom) (GB), Global University (LB)
Openalex Percentile: Top 34%
Magnetic confinement fusion research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

The Economic Burden of Patients with Diabetic Peripheral Neuropathic Pain Based on a Real-World Study in China · SHILAP Revista de lepidopterología (2025) | TGRS Research Map | TGRS